(March 19 20:30) Forbes.com
The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimers, has seen a 7% rise over the last ten trading days, while it is up 1% over the last five trading days. However, the stock has gained a whopping 666% year-to-date. We believe the stock...
You can find the original article
here